IVM: (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
IVM is a Ligand Of Interest in 5VDI designated by the RCSB
| Best-fitted instance in this entry | |
| Other instances in this entry |
| Best-fitted instance in this entry | |
| Best-fitted PDB instances with same target (top 5) |
| Best-fitted instance in this entry | |
| Best-fitted PDB instances with different target (top 5) |
| Identifier | Ranking for goodness of fit | Ranking for geometry | Real space R factor | Real space correlation coefficient | RMSZ-bond-length | RMSZ-bond-angle | Outliers of bond length | Outliers of bond angle | Atomic clashes | Stereochemical errors | Model completeness | Average occupancy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5VDI_IVM_B_403 | 64% | 22% | 0.125 | 0.924 | 1.85 | 1.34 | 7 | 11 | 3 | 0 | 100% | 1 |
| 5VDI_IVM_C_403 | 58% | 16% | 0.134 | 0.912 | 1.92 | 1.65 | 12 | 19 | 4 | 0 | 100% | 1 |
| 5VDI_IVM_A_403 | 55% | 19% | 0.147 | 0.918 | 1.79 | 1.58 | 7 | 16 | 2 | 0 | 100% | 1 |
| 5VDI_IVM_D_403 | 52% | 17% | 0.139 | 0.895 | 1.91 | 1.58 | 10 | 18 | 6 | 0 | 100% | 1 |
| 5VDI_IVM_E_403 | 45% | 22% | 0.159 | 0.891 | 1.87 | 1.3 | 8 | 12 | 1 | 0 | 100% | 1 |
| 5VDH_IVM_B_403 | 59% | 23% | 0.138 | 0.921 | 1.83 | 1.29 | 7 | 9 | 4 | 0 | 100% | 1 |
| 3RI5_IVM_A_349 | 95% | 32% | 0.071 | 0.984 | 0.88 | 1.67 | 2 | 16 | 5 | 0 | 100% | 1 |
| 3RHW_IVM_A_348 | 61% | 30% | 0.138 | 0.929 | 0.92 | 1.75 | 2 | 15 | 1 | 0 | 100% | 1 |
| 3RIA_IVM_E_348 | 60% | 30% | 0.151 | 0.939 | 0.91 | 1.75 | 2 | 17 | 4 | 0 | 100% | 1 |
| 3RIF_IVM_E_402 | 59% | 31% | 0.127 | 0.911 | 0.9 | 1.7 | 2 | 15 | 4 | 0 | 100% | 1 |
